Mutations in matrix and SP1 repair the packaging specificity of a Human Immunodeficiency Virus Type 1 mutant by reducing the association of Gag with spliced viral RNA.
BACKGROUND
The viral genome of HIV-1 contains several secondary structures that are important for regulating viral replication. The stem-loop 1 (SL1) sequence in the 5' untranslated region directs HIV-1 genomic RNA dimerization and packaging into the virion. Without SL1, HIV-1 cannot replicate in human T cell lines. The replication restriction phenotype in the SL1 deletion mutant appears to be multifactorial, with defects in viral RNA dimerization and packaging in producer cells as well as in reverse transcription of the viral RNA in infected cells. In this study, we sought to characterize SL1 mutant replication restrictions and provide insights into the underlying mechanisms of compensation in revertants.


RESULTS
HIV-1 lacking SL1 (NLΔSL1) did not replicate in PM-1 cells until two independent non-synonymous mutations emerged: G913A in the matrix domain (E42K) on day 18 postinfection and C1907T in the SP1 domain (P10L) on day 11 postinfection. NLΔSL1 revertants carrying either compensatory mutation showed enhanced infectivity in PM-1 cells. The SL1 revertants produced significantly more infectious particles per nanogram of p24 than did NLΔSL1. The SL1 deletion mutant packaged less HIV-1 genomic RNA and more cellular RNA, particularly signal recognition particle RNA, in the virion than the wild-type. NLΔSL1 also packaged 3- to 4-fold more spliced HIV mRNA into the virion, potentially interfering with infectious virus production. In contrast, both revertants encapsidated 2.5- to 5-fold less of these HIV-1 mRNA species. Quantitative RT-PCR analysis of RNA cross-linked with Gag in formaldehyde-fixed cells demonstrated that the compensatory mutations reduced the association between Gag and spliced HIV-1 RNA, thereby effectively preventing these RNAs from being packaged into the virion. The reduction of spliced viral RNA in the virion may have a major role in facilitating infectious virus production, thus restoring the infectivity of NLΔSL1.


CONCLUSIONS
HIV-1 evolved to overcome a deletion in SL1 and restored infectivity by acquiring compensatory mutations in the N-terminal matrix or SP1 domain of Gag. These data shed light on the functions of the N-terminal matrix and SP1 domains and suggest that both regions may have a role in Gag interactions with spliced viral RNA.
Ristic
Natalia
N
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, USA.
Chin
Mario P S
MP
D020121:5' Untranslated Regions / Q000235:genetics*; D002460:Cell Line; D015488:HIV Antigens / Q000235:genetics / Q000378:metabolism*; D015497:HIV-1 / Q000235:genetics / Q000502:physiology*; D006801:Humans; D009154:Mutation; D011485:Protein Binding; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism*; D019065:Virus Assembly; D014779:Virus Replication; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000235:genetics / Q000378:metabolism*
D020121:5' Untranslated Regions; D015488:HIV Antigens; D012367:RNA, Viral; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1
Methods. 2002 Feb;26(2):182-90
12054895
J Virol. 1995 Apr;69(4):2101-9
7884856
Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5219-23
8506369
J Virol. 1996 Dec;70(12):8348-54
8970954
J Virol. 1996 May;70(5):2963-73
8627772
J Virol. 2007 Apr;81(8):4002-11
17267488
Nucleic Acids Res. 2006 Jan 12;34(1):343-52
16410614
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4945-9
8197162
J Virol. 2000 Sep;74(18):8358-67
10954535
Nucleic Acids Res. 1998 Aug 15;26(16):3667-76
9685481
J Virol. 1998 Jul;72(7):5877-85
9621049
PLoS Pathog. 2009 Oct;5(10):e1000627
19834549
J Virol. 2007 Jun;81(12):6623-31
17392359
J Mol Biol. 2007 Aug 24;371(4):1084-98
17599354
J Virol. 2008 Mar;82(5):2376-84
18094172
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13535-40
19628694
J Virol. 1993 Nov;67(11):6365-78
8411338
J Virol. 1999 Aug;73(8):7014-20
10400801
J Biol Chem. 1995 Apr 7;270(14):8209-16
7713927
J Virol. 2000 Jun;74(12):5729-35
10823883
J Virol. 1994 Aug;68(8):5013-8
8035501
J Virol. 2003 Dec;77(24):12986-95
14645555
J Virol. 1996 Sep;70(9):5902-8
8709210
Biochemistry. 1994 Nov 15;33(45):13464-74
7947755
J Virol. 2004 May;78(9):4907-13
15078972
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7577-81
8755517
J Biol Chem. 1996 Dec 27;271(52):33686-92
8969239
Biochemistry. 2008 Mar 11;47(10):3283-93
18278873
RNA. 2006 Apr;12(4):542-6
16489186
J Virol. 1995 Jun;69(6):3712-20
7745720
J Virol. 2003 Aug;77(15):8329-35
12857902
RNA. 2000 Feb;6(2):282-95
10688366
Curr Top Microbiol Immunol. 1996;214:177-218
8791728
Biochemistry. 1996 Apr 16;35(15):5075-82
8664300
Biochemistry. 2002 Apr 23;41(16):5276-82
11955077
J Virol. 2001 Nov;75(21):10543-9
11581429
Virology. 1997 Jul 7;233(2):271-9
9217051
Biochem Biophys Res Commun. 1992 Jun 30;185(3):1005-15
1627125
J Virol. 1998 Aug;72(8):6629-36
9658109
Virology. 2007 Jul 5;363(2):437-46
17336363
Proc Natl Acad Sci U S A. 1989 Nov;86(22):8964-7
2479031
J Mol Biol. 1999 May 21;288(5):911-40
10329189
J Virol. 1986 Aug;59(2):284-91
3016298
J Virol. 2007 Apr;81(7):3285-92
17229705
Nucleic Acids Res. 2003 Jul 1;31(13):3406-15
12824337
Retrovirology. 2007 Dec 13;4:90
18078509
AIDS Rev. 2009 Apr-Jun;11(2):91-102
19529749
J Virol. 1997 May;71(5):3397-406
9094609
Nucleic Acids Res. 2008 Mar;36(5):1578-88
18216043
Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):9002-7
15956186
PLoS Biol. 2008 Apr 29;6(4):e96
18447581
Virology. 1998 Nov 10;251(1):1-15
9813197
J Virol. 1997 Mar;71(3):2050-8
9032337
J Virol. 1996 Oct;70(10):6723-32
8794309
Front Biosci. 2003 Jan 01;8:d135-42
12456352
J Mol Biol. 2000 Aug 11;301(2):491-511
10926523
Mol Biotechnol. 1996 Jun;5(3):233-41
8837029
Nucleic Acids Res. 2007;35(8):2695-704
17426127
J Mol Biol. 2008 Apr 11;377(5):1324-33
18314135
J Virol. 2000 Jan;74(1):541-6
10590146
Nucleic Acids Res. 2007;35(21):7288-302
17959647
J Virol. 1997 May;71(5):3407-14
9094610